Hu Changfeng, Lu Lu, Wan Jie-Ping, Wen Chengping
College of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou. China.
The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310053. China.
Curr Med Chem. 2017;24(20):2241-2249. doi: 10.2174/0929867324666170316115938.
Hydroxychloroquine (HCQ) is known as one of the most fascinating synthetic antimalarial drugs during the last 50 years. It is currently among the most commonly employed medicines for the clinical treatment of rheumatic diseases, especially systemic lupus erythematosus and rheumatoid arthritis. In related mechanism studies, it has been found that HCQ possesses various immunomodulatory and anti-inflammatory activities. In addition, the effects of HCQ on anti-platelet, metabolic pathways, and antineoplasticity have also been disclosed in more recent studies. These significant findings on HCQ suggest the potential therapeutic applications of HCQ for treatment of many diseases, such as cancers, skin disease, antiphospholipid syndrome, etc. This review focuses on recent in vitro and clinical trials on its pharmacological mechanisms, therapeutic activities, and potential adverse effects.
羟氯喹啉(HCQ)是过去50年中最引人注目的合成抗疟药物之一。它目前是临床治疗风湿性疾病,尤其是系统性红斑狼疮和类风湿性关节炎最常用的药物之一。在相关机制研究中,已发现HCQ具有多种免疫调节和抗炎活性。此外,最近的研究还揭示了HCQ在抗血小板、代谢途径和抗肿瘤方面的作用。这些关于HCQ的重要发现表明,HCQ在治疗许多疾病,如癌症、皮肤病、抗磷脂综合征等方面具有潜在的治疗应用价值。本综述重点关注其药理机制、治疗活性和潜在不良反应的近期体外和临床试验。
Expert Opin Drug Saf. 2011-3-22
Ann Rheum Dis. 1998-10
Expert Opin Drug Saf. 2017-3
J Rheumatol. 2012-6
South Afr J Crit Care. 2020-7-30
Pharmaceuticals (Basel). 2021-12-22
Evid Based Complement Alternat Med. 2021-10-21
J Pharm Anal. 2021-12